Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the future of biosimilars in oncology.
Martina Weise, MD
Advertisement
Articles by Martina Weise, MD
Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the value of biosimilars in oncology.
Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.
Advertisement
Latest Updated Articles
Dr. Weise Discusses Challenges With Biosimilar Acceptance in OncologyPublished: October 25th 2018 | Updated:
Dr. Weise Discusses the Value of Biosimilars in OncologyPublished: October 31st 2018 | Updated:
Dr. Weise Discusses the Future of Biosimilars in OncologyPublished: November 9th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5